Amplifica Announces First-in-Human Study Initiated

Amplifica’s AMP-303 safety and tolerability study targeting hair loss SAN DIEGO, June 28, 2023 /PRNewswire/ — Amplifica Holdings Group, Inc. (“Amplifica”), a privately held, clinical-stage biopharmaceutical company announced the initiation of the first-in-human study of its lead…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.